ARS Pharmaceuticals (SPRY) Competitors

Regencell Bioscience (NASDAQ:RGC) and ARS Pharmaceuticals (NASDAQ:SPRY) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Is RGC or SPRY more profitable?

Regencell Bioscience has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -16.11%. Regencell Bioscience's return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
ARS Pharmaceuticals	-16.11%	-6.94%	-5.60%

Do institutionals and insiders hold more shares of RGC or SPRY?

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has stronger valuation and earnings, RGC or SPRY?

ARS Pharmaceuticals has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$4.30M	N/A	N/A
ARS Pharmaceuticals	$89.15M	18.35	$8M	-$0.16	-104.13

Does the media favor RGC or SPRY?

In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for ARS Pharmaceuticals and 2 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.90 beat ARS Pharmaceuticals' score of 1.24 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ARS Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend RGC or SPRY?

ARS Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 86.07%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ARS Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Which has more volatility and risk, RGC or SPRY?

Regencell Bioscience has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Summary

ARS Pharmaceuticals beats Regencell Bioscience on 9 of the 14 factors compared between the two stocks.